[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 26, 2000

Intra-arterial Prourokinase for Acute Ischemic Stroke

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;283(16):2102-2104. doi:10.1001/jama.283.16.2101

To the Editor: The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) investigators1 reported a benefit of intra-arterial prourokinase compared with placebo for treating patients with acute occlusions of the middle cerebral artery. I am concerned about the appropriateness of the placebo control group for this study. Clinical trial design must compare any proposed therapies with the best available medical treatment. For patients presenting within 3 hours of ischemic stroke onset, the Food and Drug Administration (FDA) has approved intravenous (IV) tissue-type plasminogen activator (tPA). However, because of the study design, some subjects in the placebo group may have been denied this treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×